Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026

Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spree. Biogen bets $5.6B on Apellis complement therapies. FDA warns of 8deaths linked to Amgen's Tavneos liver safety signal.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Centessa Pharmaceuticals, Biogen, Apellis Pharmaceuticals, Amgen, Tavneos, avacopan,orexin, narcolepsy, AstraZeneca, efzimfotase alfa, hypophosphatasia, Agios, mitapivat, sickle cell disease, Novo Nordisk, Wegovy, Merck, Infinimmune, M&A, acquisitions, Lilly